3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Myeloid
1
Classical hematology
1
Conditions
Venous Thromboembolism
1
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Hemorrhage
1
Interventions
venetoclax
33
fludarabine
32
Cyclophosphamide
31
Azacitidine
29
Specimen Handling
27
Biopsy
19
Cytarabine
18
fludarabine phosphate
15
Whole-Body Irradiation
15
Stem Cell Transplantation
15
Decitabine
15
ruxolitinib
14
Tacrolimus
14
Melphalan
14
Busulfan
14
Mycophenolic Acid
13
asciminib
10
Injections
10
decitabine and cedazuridine drug combination
8
Thiotepa
8
Methotrexate
8
Hematopoietic Stem Cell Transplantation
8
X-Rays
7
Granulocyte Colony-Stimulating Factor
7
Magnetic Resonance Spectroscopy
6
Idarubicin
6
Filgrastim
6
Cyclosporine
6
Blood Specimen Collection
6
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
N(4)-oleylcytosine arabinoside
×
Myeloid
×
Clear all
NCT05198960
2026-03-20
AVAJAK
University Hospital, Brest
Phase 3
Recruiting
1,308 enrolled